Photo from wikipedia
Daratumumab, a human anti‐CD38 monoclonal antibody used to treat multiple myeloma, interferes with pretransfusion testing and can mask alloantibodies. Incidence of alloimmunization in patients on daratumumab has not been well… Click to show full abstract
Daratumumab, a human anti‐CD38 monoclonal antibody used to treat multiple myeloma, interferes with pretransfusion testing and can mask alloantibodies. Incidence of alloimmunization in patients on daratumumab has not been well characterized, and optimal transfusion guidelines regarding prophylactic antigen matching, accounting for both patient safety and efficiency, have not been well established for these patients.
Keywords:
daratumumab;
multiple myeloma;
transfusion;
transfusion management;
optimizing transfusion
Journal Title: Transfusion
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Transfusion
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!